AB197650

Anti-CD22 antibody - C-terminal

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Polyclonal CD22 antibody. C-terminal. Suitable for IHC-P, WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human CD22 aa 800-850.

View Alternative Names

CD22, SIGLEC2, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14, BL-CAM, Siglec-2

2 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD22 antibody - C-terminal (AB197650)

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD22 antibody - C-terminal (AB197650)

Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labeling CD22 with ab197650 at 1 μg/ml.

Western blot - Anti-CD22 antibody - C-terminal (AB197650)

WB

Supplier Data

Western blot - Anti-CD22 antibody - C-terminal (AB197650)

All lanes:

Western blot - Anti-CD22 antibody - C-terminal (ab197650) at 0.5 µg/mL

All lanes:

Raji cell lysate

Predicted band size: 95 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P, WB

Immunogen

Synthetic Peptide within Human CD22 aa 800-850. The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Alternative Products

Primary Antibodies

AB207727

Anti-CD22 antibody [EPR20061]

20ul selling size|RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-CD22 antibody [EPR20061] (AB207727)

4
2

Primary Antibodies

AB32355

Anti-CD22 (phospho Y842) antibody [Y507]

RabMAb|Recombinant

Western blot - Anti-CD22 (phospho Y842) antibody [Y507] (AB32355)

0
0

Primary Antibodies

AB33859

Anti-CD22 antibody [EP498Y]

RabMAb|Recombinant

Western blot - Anti-CD22 antibody [EP498Y] (AB33859)

0
0

Primary Antibodies

AB240404

Anti-CD22 antibody [SP104] - BSA and Azide free

RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD22 antibody [SP104] - BSA and Azide free (AB240404)

0
0

Primary Antibodies

AB246334

Anti-CD22 antibody [EPR20061] - BSA and Azide free

RabMAb|Recombinant

Immunocytochemistry/ Immunofluorescence - Anti-CD22 antibody [EPR20061] - BSA and Azide free (AB246334)

0
0

Primary Antibodies

AB32123

Anti-CD22 (phospho Y822) antibody [Y506]

RabMAb|Recombinant

Flow Cytometry (Intracellular) - Anti-CD22 (phospho Y822) antibody [Y506] (AB32123)

3
1

Primary Antibodies

AB32040

Anti-CD22 (phospho Y807) antibody [Y505]

RabMAb|Recombinant

Western blot - Anti-CD22 (phospho Y807) antibody [Y505] (AB32040)

0
0

Complementary Products

Primary Antibodies

AB64088

Anti-CD20 antibody [SP32]

BOND RX™ Validated|20ul selling size|RabMAb|Advanced Validation|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD20 antibody [SP32] (AB64088)

5
12

Primary Antibodies

AB10558

Anti-CD45 antibody

BOND RX™ Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD45 antibody (AB10558)

4
63

Primary Antibodies

AB239075

Anti-CD86 antibody [EPR21962]

20ul selling size|RabMAb|Recombinant|KO Validated

Flow Cytometry - Anti-CD86 antibody [EPR21962] (AB239075)

0
0

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

5
20

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "0.5-1 µg/mL", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "0.1-0.5 µg/mL", "WB-species-notes": "<p></p>" } } }

style

left-column

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Immunogen

Storage buffer

Preservative: 0.025% Sodium azide, 0.025% Thimerosal (merthiolate) Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Disodium hydrogenorthophosphate

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs).

Biological function summary

CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis.

Pathways

CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response.

CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed : 34330755, PubMed : 8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed : 20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed : 8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed : 20516366).

See full target information CD22

style

left-column

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Journal of tissue engineering 13:20417314221118858 PubMed36003955

2022

Mesenchymal stem cells establish a pro-regenerative immune milieu after decellularized rat uterus tissue transplantation.

Applications

Unspecified application

Species

Unspecified reactive species

Edina Sehic,Emy Thorén,Ingigerdur Gudmundsdottir,Mihai Oltean,Mats Brännström,Mats Hellström

NPJ vaccines 6:117 PubMed34584101

2021

Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Woods,Vanessa Zaiatz-Bittencourt,Ciaran Bannan,Colm Bergin,David K Finlay,Matthias Hoffmann,Anthony Brown,Bethany Turner,Shokouh Makvandi-Nejad,Ventzi Vassilev,Stefania Capone,Antonella Folgori,Tomáš Hanke,Eleanor Barnes,Lucy Dorrell,Clair M Gardiner

International journal of nanomedicine 12:3767-3784 PubMed28553113

2017

Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats.

Applications

Unspecified application

Species

Unspecified reactive species

Raul C Maranhão,Maria C Guido,Aline D de Lima,Elaine R Tavares,Alyne F Marques,Marcelo D Tavares de Melo,Jose C Nicolau,Vera Mc Salemi,Roberto Kalil-Filho

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com